Top 10 Companies in the (R)-1-(3-Bromophenyl)-ethylamine (CAS 176707-77-0) Market (2026): Market Leaders Powering Global Chemistry

MARKET INSIGHTS

The Global (R)-1-(3-Bromophenyl)-ethylamine (CAS 176707-77-0) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.6 million by 2034, exhibiting a CAGR of 7.2% during the forecast period.

(R)-1-(3-Bromophenyl)-ethylamine (CAS 176707-77-0) is a chiral primary amine compound featuring a bromine substituent at the meta position of the phenyl ring. As an enantiomerically pure building block, it plays a critical role in asymmetric synthesis and pharmaceutical manufacturing, serving as a key intermediate in the development of active pharmaceutical ingredients (APIs), agrochemicals, and specialty fine chemicals.

The market is witnessing steady growth driven by rising demand for enantioselective synthesis in drug discovery and the expanding pipeline of chiral pharmaceuticals globally. Furthermore, increasing applications in contract research and manufacturing organizations (CROs and CMOs) are reinforcing demand. Key suppliers operating in this space include Sigma‑Aldrich (Merck KGaA), TCI Chemicals, and Combi‑Blocks, among other fine chemical manufacturers catering to research and industrial-scale requirements.

(R)-1-(3-Bromophenyl)-ethylamine (CAS 176707-77-0) Market – View in Detailed Research Report

MARKET DRIVERS

Rising Demand in Pharmaceutical Synthesis

The global market for (R)-1-(3-Bromophenyl)-ethylamine (CAS 176707-77-0) has been propelled by its critical role as a chiral building block in pharmaceutical intermediates. This enantiomerically pure compound is essential for synthesizing bioactive molecules targeting central nervous system disorders and oncology drugs. With pharmaceutical R&D investments surpassing USD 200 billion annually, demand for high‑purity chiral amines like this one continues to surge, driving market growth at a robust pace.

Technological Advancements in Production

Improvements in asymmetric synthesis and biocatalytic processes have significantly reduced production costs while enhancing yield and purity levels above 99% ee. These innovations allow manufacturers to scale up efficiently, meeting the needs of contract development and manufacturing organizations (CDMOs). Furthermore, the compound’s versatility in cross‑coupling reactions supports its adoption in diverse drug discovery pipelines.

➤ Market expansion is further fueled by a 7.2% CAGR projected through 2030, with Asia‑Pacific leading production hubs due to cost advantages.

While regulatory approvals accelerate for novel therapeutics incorporating this amine, ongoing collaborations between chemical suppliers and pharma giants ensure a steady supply chain. This synergy not only boosts volume sales but also opens doors for customized derivatives.

MARKET CHALLENGES

Supply Chain Vulnerabilities

Fluctuations in raw material availability, particularly brominated aromatics, pose significant hurdles for consistent production of (R)-1-(3-Bromophenyl)-ethylamine. Geopolitical tensions and logistics disruptions have led to price volatility, with costs rising up to 15% in recent quarters. Manufacturers struggle to maintain inventory levels amid unpredictable demand from batch‑based pharma orders.

Other Challenges

High Purification Costs
Achieving enantiomeric excess through chromatography or enzymatic resolution inflates expenses, limiting scalability for smaller players. However, larger firms invest in continuous flow technologies to mitigate this.

Intellectual property disputes over synthesis patents further complicate market entry, delaying product launches. While demand grows, these factors create bottlenecks, especially in emerging regions.

MARKET RESTRAINTS

Strict Regulatory Compliance

Stringent guidelines from agencies like the FDA and EMA on impurity profiles and genotoxic impurities heavily impact the (R)-1-(3-Bromophenyl)-ethylamine market. Compliance requires extensive testing, pushing validation costs beyond USD 500,000 per batch for some producers. This restraint slows market penetration, particularly for novel applications.

High entry barriers due to specialized equipment needs deter new competitors, consolidating supply among a few key players. Environmental regulations on brominated waste disposal add another layer, increasing operational overheads by 20‑25%.

Because of these factors, smaller markets in developing regions face delays, even as global pharma pipelines expand. However, established firms navigate these through proven GMP certifications.

MARKET OPPORTUNITIES

Expansion into Emerging Therapeutics

Growing pipelines for CNS and anticancer drugs present untapped potential for (R)-1-(3-Bromophenyl)-ethylamine as a key intermediate. With over 50 clinical trials referencing similar chiral scaffolds, partnerships with biotech startups could double market volumes by 2028.

Shifts toward sustainable synthesis, including metal‑free catalysis, align with green chemistry trends, attracting eco‑conscious buyers. Asia‑Pacific’s manufacturing boom offers cost‑effective scaling opportunities.

Furthermore, custom synthesis services for agrochemicals and material sciences could diversify revenue streams beyond pharma, projecting a market value exceeding USD 120 million by decade’s end.

Top 10 Companies in the (R)-1-(3-Bromophenyl)-ethylamine Market

1️⃣ Hairui Fine Chemical Co., Ltd.

Headquarters: Shenzhen, China
Key Offering: High‑purity (R)-1-(3‑Bromophenyl)-ethylamine, custom synthesis services

Hairui Fine Chemical has emerged as a leading supplier of enantiomerically pure chiral amines, leveraging state‑of‑the‑art asymmetric synthesis platforms. Its robust GMP‑compliant production lines cater to both pharmaceutical manufacturers and CDMOs.